Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1994-05-31
1997-02-11
Scheiner, Toni R.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 79, 435 792, 436506, 436 64, 436813, G01N 3353, G01N 33574
Patent
active
056019890
ABSTRACT:
Methods for the detection, monitoring and treatment of malignancies are disclosed. Detection of the proliferation of T cells in response to in vitro exposure to a protein expression product of an activated oncogene or cancer-related gene associated with a malignancy, or detection of immunocomplexes formed between the protein expression product and antibodies in body fluid, allows the diagnosis of the presence of a malignancy. The present invention also discloses methods and compositions for treating a malignancy.
REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 4411990 (1983-10-01), Salmon et al.
patent: 4643968 (1987-02-01), Weaver
patent: 4820631 (1989-04-01), Lacal et al.
patent: 4861589 (1989-08-01), Ju et al.
Balmain, A., "Transforming ras oncogenes and multistage carcinogenesis," British Journal of Cancer 51: 1-7, 1985.
Balmain et al., "An Approach to the Molecular Mechanism of Cancer Induction," Journal of Pathology 149: 3-8, 1986.
Bloch, A., "Growth and differentiation signals as determinants of cancer cell proliferation," Chemical Abstracts 111(21): Abstract # 192290z, 1989.
Bodmer, W., "T-cell immune response to cancer--a new look," Hum. Immunol. 30(4): 259-261, 1991.
Bos et al., "Prevalence of ras gene mutations in human colorectal cancers," Nature 327: 293-297, 1987.
Bos, J., "The ras gene family and human carcinogenesis," Mutation Research 195: 255-271, 1988.
Bos, J., "ras Oncogenes in Human Cancer: A Review," Cancer Research 49: 4682-4689, 1989.
Brown et al., "Protein Antigens of Normal and Malignant Human Cells Identified by Immunoprecipitation with Monoclonal Antibodies," Journal of Biological Chemistry 255(11):4980-4983, 1980.
Carney, W., "Human tumor antigens and specific tumor therapy," Immunology Today 9(12):363-364, 1988.
Carney et al., "Monoclonal Antibodies for Detecting Oncogenic ras Proteins in Cancer Cells," Clinical Chemistry 34: 1698-1699, 1988.
Chardin, P., "The ras superfamily proteins," Biochimie 70:865-868, 1988.
"Clinical Laboratory Methods for Detection of Cellular Immune Function," (eds.), Stites, Stobo and Wells, Basic and Clinical Immunology (Sixth edition) Appleton & Lange, 1987, pp. 295-298.
Dotsika and Sanderson, "A fluorometric assay for determining cell growth in lymphocyte proliferation and lymphokine assays," Chemical Abstracts 108(5): abstract # 35974w, 1988.
Drebin et al., "Preliminary Evidence of an Association Between an Activated Cellular Transforming Gene and a Tumor-Specific Transplantation Antigen," UCLA Symposium on Molec. & Cell Biology 24:223-225, 1982.
Feramisco et al., "Microinjection of the Oncogene Form of the Human H-ras (T-24) Protein Results in Rapid Proliferation of Quiescent Cells," Cell 38:109-117, 1984.
Forrester et al., "Detection of high incidence of K-ras oncogenes during human colon tumorigenesis," Nature 327:298-303, 1987.
Gehly et al., "Chimeric BCR-abl Messenger RNA as a Marker for Minimal Residual Disease in Patients Transplanted for Philadelphia Chromosomes-Positive Acute Lymphoblastic Leukemia," Blood 78:458-465, 1991.
Hand et al., "Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas," Proc. Natl. Acad. Sci. USA 81:5227-5231, 1984.
Huber, B., "Therapeutic opportunities involving cellular oncogenes: novel approaches fostered by biotechnology," FASEB Journal 3:5-13, 1989.
Jung and Schluesener, "Human T Lymphocytes Recognize a Peptide of Single Point-mutated, Oncogenic ras Proteins," Journal of Experimental Medicine 173:273-276, 1991.
Marx, J., "Gene Signals Relapse of Breast, Ovarian Cancers," Science 244:654-655, 1989.
McLaughlin et al., "In Vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome," Proc. Natl. Acad. Sci. USA 84:6558-6562, 1987.
McLaughlin et al., "Alternative Forms of the BRC-ABL Oncogene Have Quantitatively Different Potencies for Stimulation of Immature Lymphoid Cells," Mol. and Cell. Biol. 9:1866-1874, 1989.
Nathan and Oski (eds.), Hematology Of Infancy and Childhood 2, 4th ed., W. B. Saunders Co., Philadelphia, p. 1134.
Nigro et al., "Mutations in the p53 gene occur in diverse human tumour types," Nature 342:705-707, 1989.
Niman et al., "Anti-peptide antibodies detect oncogene-related proteins in urine," Proc. Natl. Acad. Sci. USA 82: 7924-7928, 1985.
Peace et al., "T Cells Immune To The p21 Product Of An Activated ras Proto-Oncogene Can Be Elicited By Immunization With Peptides Corresponding To The Mutated Protein Segment," FASEB Journal 4(7): Abstract # 1854, p. A2013, 1990.
Raines and Ross, "Platelet-derived Growth Factor," Journal of Biological Chemistry 257(9):5154-5160, 1982.
Reddy et al., "A point mutation is responsible for the acquistion of transforming properties by the T24 human bladder carcinoma oncogene," Nature 300: 149-152, 1982.
Rodenhuis et al., "Mutational Activation of the K-ras Oncogene: A Possible Pathogenetic Factor in Adenocarcinoma of the Lung," New England Journal of Medicine 317(15):929-935, 1987.
Santos and Nebreda, "Structural and functional properties of ras proteins," FASEB Journal 3:2151-2163, 1989.
Shih and Weeks, "Oncogenes and Cancer: The p21 ras Genes," Cancer Investigation 2(2):109-123, 1984.
Slamon et al., "Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer," Science 244:707-712, 1989.
Stacey and Kung, "Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein," Nature 310:508-511, 1984.
Tanaka et al., "Efficient generation of antibodies to oncoproteins by using synthetic peptide antigens," Proc. Natl. Acad. Sci. USA 82:3400-3404, 1985.
Thor et al., "Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases," Nature 311:302-303, 1984.
Weiner et al., "A point mutation in the neu oncogene mimics ligand induction of receptor aggregation," Nature 339:230-231, 1989.
Yandell et al., "Oncogenic Point Mutations in the Human Retinoblastoma Gene: Their Application to Genetic Counseling," New England Journal of Medicine 321:1689-1695, 1989.
Ben-Mahrez, K., et al., Br. J. Cancer, vol. 57, pp. 529-534, 1988.
Ben-Mahrez, K., et al., Int. J. Cancer, vol. 46, pp. 35-38, 1990.
Wisdom, G. B., Clin. Chem., vol. 22, No. 8, pp. 1243-1255 (1976).
Cheever Martin A.
Peace David J.
Scheiner Toni R.
Washington Research Foundation
LandOfFree
Immune reactivity to expressed activated oncogenes for diagnosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immune reactivity to expressed activated oncogenes for diagnosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune reactivity to expressed activated oncogenes for diagnosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-341083